Allyes Biotech: Board of Directors Resolves to Issue Common Shares through Global Depository Receipts for Capital Increase
Allyes Biotech's Board of Directors resolved to conduct a capital increase by issuing up to 40 million common shares through Global Depository Receipts (GDRs). This move aims to fund R&D expenditures, bolster working capital, support long-term strategic alliances, and meet future capital demands.
📋 Article Processing Timeline
- 📰 Published: May 7, 2026 at 09:00
- 🔍 Collected: May 8, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 8, 2026 at 08:41 (41 min after Collected)
1. Date of Board of Directors resolution: May 7, 2026
2. Source of capital increase funds: Capital increase by issuing common shares through Global Depository Receipts
3. Whether new shares will be issued under an overall shelf registration (Yes, please specify the planned issuance period / No): No
4. Total amount and number of shares to be issued in the entire plan (if for earnings or capital reserve capitalization, the number of shares does not include those allocated to employees): The issuance of common shares for Global Depository Receipts shall not exceed 40,000 thousand shares. The total issuance amount will depend on the number of shares issued and the actual issuance price per share.
5. For overall shelf registration cases, the amount and number of shares issued this time: Not applicable
6. For overall shelf registration cases, the remaining amount and number of shares after this issuance: Not applicable
7. Par value per share: NT$10
8. Issuance price: The actual issuance price shall be authorized to the Chairman and/or his designated person to negotiate and determine with the securities underwriter.
9. Number of shares subscribed by employees or allocation amount: 10% to 15% of the total new shares issued shall be reserved for subscription by eligible employees of the company and its controlled or affiliated companies.
10. Public offering shares: In accordance with Article 267 of the Company Act, excluding the 10% to 15% of the total new shares reserved for subscription by eligible employees of the company and its controlled or affiliated companies, the remaining 85% to 90% will be publicly offered through Global Depository Receipts, after the shareholders' meeting resolves to waive the priority subscription rights of existing shareholders, in accordance with Article 28-1 of the Securities Exchange Act.
11. Proportion of subscription by original shareholders or free allocation: Not applicable
12. Handling of odd lots and unsubscribed shares: If there are insufficient subscriptions by employees, the Chairman is authorized to arrange for specific individuals to subscribe at the issuance price, or to include them as original securities for Global Depository Receipts based on market demand.
13. Rights and obligations of new shares issued this time: Same as existing common shares.
14. Purpose of capital increase funds: R&D expenditures, or strengthening working capital, or other long-term strategic alliance development, or other capital needs to meet the company's future development.
15. Other matters to be specified: None
2. Source of capital increase funds: Capital increase by issuing common shares through Global Depository Receipts
3. Whether new shares will be issued under an overall shelf registration (Yes, please specify the planned issuance period / No): No
4. Total amount and number of shares to be issued in the entire plan (if for earnings or capital reserve capitalization, the number of shares does not include those allocated to employees): The issuance of common shares for Global Depository Receipts shall not exceed 40,000 thousand shares. The total issuance amount will depend on the number of shares issued and the actual issuance price per share.
5. For overall shelf registration cases, the amount and number of shares issued this time: Not applicable
6. For overall shelf registration cases, the remaining amount and number of shares after this issuance: Not applicable
7. Par value per share: NT$10
8. Issuance price: The actual issuance price shall be authorized to the Chairman and/or his designated person to negotiate and determine with the securities underwriter.
9. Number of shares subscribed by employees or allocation amount: 10% to 15% of the total new shares issued shall be reserved for subscription by eligible employees of the company and its controlled or affiliated companies.
10. Public offering shares: In accordance with Article 267 of the Company Act, excluding the 10% to 15% of the total new shares reserved for subscription by eligible employees of the company and its controlled or affiliated companies, the remaining 85% to 90% will be publicly offered through Global Depository Receipts, after the shareholders' meeting resolves to waive the priority subscription rights of existing shareholders, in accordance with Article 28-1 of the Securities Exchange Act.
11. Proportion of subscription by original shareholders or free allocation: Not applicable
12. Handling of odd lots and unsubscribed shares: If there are insufficient subscriptions by employees, the Chairman is authorized to arrange for specific individuals to subscribe at the issuance price, or to include them as original securities for Global Depository Receipts based on market demand.
13. Rights and obligations of new shares issued this time: Same as existing common shares.
14. Purpose of capital increase funds: R&D expenditures, or strengthening working capital, or other long-term strategic alliance development, or other capital needs to meet the company's future development.
15. Other matters to be specified: None